CHD, Stroke Risk Up in Kidney Stone Patients
"Other metabolic abnormalities presenting mostly in stone formers, such as hypercalciuria, hyperuricemia, and hyperoxaluria, may proceed through the lack of effective calcification inhibitors, which were found to be deficient in blood and urine," they ...
MedPage Today - Mon, 08 Sep 2014 07:15

Dicerna On Track with Drug Candidates, Initial Cancer Rx Data Expected in '15
NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this month confirmed previous guidance on its two drug candidates, the solid tumor therapy DCR-MYC and the primary hyperoxaluria 1 (PH1) treatment DCR-PH1, stating that both agents remain on track ...
GenomeWeb - Thu, 21 Aug 2014 07:30


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014